#hairy cell leukemia

Immunotoxin Lumoxiti fills an unmet need for patients whose disease has progressed after trying other FDA-approved therapies.

Moxetumomab pasudotox “offers an option for patients with relapsed or refractory hairy cell leukemia that avoids additional chemotherapy.”